What is in KLOW?
KLOW contains GHK-Cu, BPC-157, TB-500, and KPV. Products sold as KLOW usually list GHK-Cu, BPC-157, TB-500, and KPV in one vial. The amounts and ratios differ from seller to seller, and research-chemical labels are not verified by any drug standard. PeptideAgent does not name or link sellers.
Also searched as: Klow peptide blend; KLOW blend; GHK-Cu, BPC-157, TB-500, and KPV blend.
| Ingredient | Why it is in the mix | Status (alone) |
|---|---|---|
| GHK-Cu | Sold as the skin, collagen, and hair component, based mainly on topical cosmetic studies. |
|
| BPC-157 | Sold as the tissue healing and gut component, based on rodent studies. |
|
| TB-500 | Sold as the recovery and wound repair component, based on animal studies of full-length thymosin beta-4, a different substance from TB-500. |
|
| KPV | Added as the anti-inflammatory component, based on mouse colitis studies. |
|
Grades and statuses come from each peptide's own record and update with it. Grades follow the methodology.
Why are these peptides combined in KLOW?
KLOW is marketed as GLOW with an anti-inflammatory added. The claimed benefits are the GLOW claims (skin and collagen from GHK-Cu, tissue healing from BPC-157 and TB-500) plus calmer inflammation, especially in the gut and skin, from KPV.
KPV is the last three amino acids of alpha-melanocyte stimulating hormone. In two independent 2008 mouse studies, KPV given by mouth reduced chemically induced colitis, with lower inflammatory markers and faster recovery. Those two studies are the whole evidence base for the KPV part of the pitch. [1] [2] [3] [6]
Has KLOW been studied?
No published study has tested KLOW, or any mix of GHK-Cu, BPC-157, TB-500, and KPV, in humans or animals.
Every ingredient has the same gap on its own. There is no human trial of injected GHK-Cu. BPC-157 has preclinical work and three small uncontrolled pilot reports (knee pain, interstitial cystitis, IV safety). No human study of TB-500 itself has been identified. The small phase 1 and phase 2 human trials often cited for it (IV safety, eye drops for dry eye, a topical form for skin ulcers) tested full-length thymosin beta-4, which FDA says is not the same substance as TB-500. KPV has no human trial for any use, and the mouse studies gave it by mouth, not by injection.
Adding a fourth peptide multiplies the unknowns rather than the evidence: stability in a shared vial, interactions between the peptides, and additive side effects have not been studied. [2] [4] [7] [8] [13] [14] [15] [16]
What each ingredient has shown alone
- GHK-Cu (human RCT evidence). Copper binding peptide used in skin cosmetics; one small randomized topical trial found no objective benefit. Injectable form is unapproved and untested.
- BPC-157 (animal-only evidence). A 15 amino acid peptide with strong animal healing data, no randomized human trial in PubMed, and a draft HHS compounding policy from October 2026.
- TB-500 (animal-only evidence). Synthetic 7 amino acid fragment of thymosin beta-4. No human study of TB-500 itself; the human trials used the full-length protein. WADA banned.
- KPV (animal-only evidence). Anti-inflammatory fragment of the hormone alpha-MSH; mouse colitis data, no human trial; topical and oral use in HHS's October 2026 draft policy.
KLOW results and before and after claims
KLOW before and after claims rest on photos and testimonials, not measured outcomes. No study has measured skin, gut, joint, or recovery outcomes after injecting KLOW or any of its four peptides in people.
The closest measured human data are small topical GHK-Cu cosmetic studies, which used a cream rather than an injection. For KPV, the measured outcomes are colitis scores in mice.
A 2026 review of peptides marketed for recovery notes that placebo effects, amplified by social media, can explain much of what users report. Claimed KLOW benefits should be read as untested. [2] [3] [8]
What are the side effects of KLOW?
No study has recorded the side effects of KLOW. The injectable forms of all four ingredients lack systematic human safety data.
Reported and theoretical concerns include injection site pain and irritation, the untested possibility that growth-promoting peptides affect existing tumors, and, for KPV, a theoretical effect on the response to infection because it dampens inflammatory signaling. None of these has been studied in people.
Unregulated manufacturing adds risk. The BPC-157 systematic review warns that contamination and wrong content are possible in products made outside drug standards, and a four-peptide vial is harder to verify than a single peptide. [1] [5] [7] [8]
Reported for each ingredient
From each peptide's record. These were reported for the peptide alone, not for the blend. Absence of data is not evidence of safety.
| Ingredient | Reported side effects and safety notes |
|---|---|
| GHK-Cu |
|
| BPC-157 |
|
| TB-500 |
|
| KPV |
|
Is KLOW legal?
A blend inherits the strictest status among its ingredients, because a mixed product is only as lawful as its least lawful component. For KLOW that is GHK-Cu, BPC-157, TB-500, and KPV: no federal basis to compound. At least one ingredient is not FDA approved and not on the 503A bulks list, so a licensed pharmacy has no federal basis to compound the mix.
- GHK-Cu regulatory timeline (Nomination withdrawn)
- BPC-157 regulatory timeline (HHS interim policy (draft))
- TB-500 regulatory timeline (HHS interim policy (draft))
- KPV regulatory timeline (HHS interim policy (draft))
Why blends like this are sold as research chemicals
A drug for human use in the United States has to be FDA approved or lawfully compounded by a licensed pharmacy for a named patient under a prescription. This blend can be neither, so vials sold under its name carry labels such as “for research use only” or “not for human consumption”. That label does not make a product lawful to inject, and it means no one has checked the vial for identity, purity, sterility, or amount. [10]
WADA status
BPC-157, TB-500, and KPV are prohibited at all times on the WADA list, so any product containing them is prohibited for athletes subject to anti-doping testing.
State rules: peptide laws by state. All FDA actions: regulatory tracker.
What does KLOW cost, and what can a provider lawfully offer?
There is no federal basis to compound KLOW today. A 503A pharmacy may compound from a bulk drug substance only if the substance has a USP or NF monograph, is a component of an FDA approved drug, or appears on the 503A bulks list. Injectable GHK-Cu meets none of those conditions: its nomination was withdrawn, it is not on the bulks list, and it was not reviewed by the Pharmacy Compounding Advisory Committee in July 2026. A mix containing it has no federal basis to be compounded.
BPC-157, TB-500, and KPV are not on the 503A bulks list either. On October 28, 2026, HHS released a draft enforcement discretion policy for six peptides, including these three, that covers only single-ingredient compounded products made under strict conditions. Blends such as KLOW are not covered, and KPV is limited to topical and oral use, not injection. The policy is a draft, not an FDA approval, and does not add any of them to the bulks list. At the July 2026 meeting, FDA's drug center recommended against listing each and the committee voted in favor, according to Appendix B of the HHS policy. Injectable GHK-Cu was not part of that review.
Advertised KLOW prices come from research-chemical sellers and clinics and are not a lawful price. Topical GHK-Cu cosmetics, sold without drug claims, can be sold without a prescription; the HHS draft policy addresses only single-ingredient compounded products on a prescription, not KLOW. [9] [10] [11] [17] [18]
What's actually offered, and what that means for you
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [19] [20] [21]
Being offered does not change the legal status of KLOW. GHK-Cu, BPC-157, TB-500, and KPV are not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound the mix. [10] [22]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [19] [22] [23] [24] [25] [26]
What that means for you
- A pharmacy that compounds KLOW is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [19] [23]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [26]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [27]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [28] [29]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [22]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, KLOW contains at least one ingredient that is prohibited under the WADA Prohibited List. [12]
If you're going ahead anyway
These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound KLOW, with or without a prescription. [10]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [30] [31] [32]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [21] [32] [33]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [26] [34] [35] [36] [37] [38]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [26]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [30]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [21]
- Pharmacy: Is this made for me on a prescription written in my name? [33]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [21] [32]
- Prescriber: What is the legal basis for a pharmacy to compound KLOW? Is it FDA approved or on the 503A bulks list? [10] [26]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [21]
In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [27]
Compare the ingredients
- BPC-157 vs GHK-Cu
- BPC-157 vs KPV
- BPC-157 vs TB-500
- TB-500 vs GHK-Cu
- BPC-157 vs ARA-290 (cibinetide)
- KPV vs LL-37
- Thymosin alpha-1 vs TB-500
Blends that share an ingredient
- GLOW: GLOW is a gray-market mix of GHK-Cu, BPC-157, and TB-500 sold for skin and healing. No study has tested it, and HHS's draft peptide policy excludes blends.
- Wolverine stack: The Wolverine stack pairs BPC-157 and TB-500 for injury recovery. No study has tested the pair, and HHS's draft peptide policy does not cover blends.
Frequently asked questions
What is KLOW peptide?
KLOW is a nickname for an injectable mix of GHK-Cu, BPC-157, TB-500, and KPV, sold for skin, healing, and inflammation. It is GLOW with KPV added. It is not an approved drug and has never been tested. [8] [10]
What are the claimed benefits of KLOW peptide?
Sellers claim skin, collagen, healing, and anti-inflammatory benefits. Each claim comes from studies of one ingredient, mostly in animals, or, for TB-500, from studies of full-length thymosin beta-4, a different substance. None comes from studies of KLOW itself. [2] [3] [7] [16]
What does KPV add to KLOW?
KPV is a three amino acid fragment of alpha-MSH that reduced colitis in two mouse studies when given by mouth. It has no human trial, so its contribution to an injected blend is unknown. [1] [2]
Is KLOW peptide legal?
Not as a drug for human use. Injectable GHK-Cu has no federal basis to be compounded, and HHS's October 28, 2026 draft policy covers BPC-157, TB-500, and KPV only as single-ingredient compounded products, not mixes like KLOW. [10] [18]
KLOW vs GLOW: which is better?
Neither has been tested, so neither can be called better. KLOW adds KPV, which has mouse data only, and one more ingredient whose identity and purity in a vial are unverified. [2] [8]
What are the side effects of KLOW peptide?
No study has recorded them. Injection site reactions are reported anecdotally, none of the four injected peptides has systematic human safety data, and KPV carries a theoretical concern about dampened immune responses. [1] [7]
Is KLOW allowed for tested athletes?
No. BPC-157 and KPV are prohibited under WADA section S0 and TB-500 under section S2, so a product containing them is prohibited at all times. [12]
From the blog
- Klow vs Glow peptide: what KPV adds and what is known
Klow is the Glow blend (GHK-Cu, BPC-157, TB-500) plus KPV. Each ingredient compared, what KPV is claimed to add, how both relate to the Wolverine stack, and why no study tests either blend.
- GLOW peptide before and after: what the evidence shows
No study has measured GLOW peptide before and after results. What each ingredient's human evidence shows for skin and hair, documented side effects, and the blend's legal status.
- Topical vs injectable GHK-Cu: what the evidence shows
Topical GHK-Cu has small skin studies and is a lawful cosmetic. Injectable GHK-Cu has no human trial and is not on the 503A bulks list. Evidence, absorption, safety, and legality compared.
- What is peptide therapy? What clinics sell, what is legal, and what works
Peptide therapy means three different things: FDA-approved drugs, compounded prescriptions, and research-only products. Here is how to tell them apart, what the evidence shows, and what it costs.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008PubMed 18061177, 2008
- [2]Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008PubMed 18092346, 2008
- [3]Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015PubMed 26236730, 2015
- [4]Sosne G et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial. Clin Ophthalmol 2015PubMed 26056426, 2015
- [5]Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018PubMed 29986520, 2018
- [6]Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell Tissue Res 2019)PubMed 30915550, 2019
- [7]Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025PubMed 40756949, 2025
- [8]Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med 2026PubMed 41966639, 2026
- [9]FDA: Is it a cosmetic, a drug, or both? (or is it soap?)FDA, 2024
- [10]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, October 28). KLOW peptide: what is in it and does it work?. https://peptideagent.ai/blends/klow- HTML link
<a href="https://peptideagent.ai/blends/klow">KLOW peptide: what is in it and does it work?</a>, PeptideAgent, updated October 28, 2026.